Dr. Michael Method is an oncologist and also senior medical adviser and global lead for adjuvant breast cancer treatment research at Lilly Oncology.
While ESMO 2020 was virtual this year, there was still quite a bit of breast cancer research presented. Dr. Method joined us to talk about some of the most notable studies.
Listen to the podcast to hear him discuss:

studies looking at using the CDK4/6 inhibitors Verzenio (chemical name: abemaciclib) and Ibrance (chemical name: palbociclib) to treat early-stage hormone-receptor-positive, HER2-negative breast cancer

a study using the immunotherapy Tecentriq (chemical name: atezolizumab) to treat early-stage triple-negative breast cancer before surgery